Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445737 | 0.97 | ALDH1A1 (0.54) | ALDH1A1HRH4HRH1SMN1; SMN2USP2 | |
| Hydrochloric Acid SCHEMBL31046080 | 0.97 | ALDH1A1 (0.50) | ALDH1A1HRH4HRH1SMN1; SMN2USP2 | |
| SCHEMBL5033361 | 0.97 | ALDH1A1 (0.54) | ALDH1A1HRH4HRH1SMN1; SMN2USP2 | |
| SCHEMBL3027569 | 0.95 | HRH4 (0.50) | ALDH1A1HRH4HRH1SMN1; SMN2USP2 | |
| SCHEMBL10494023 | 0.92 | SMN1; SMN2 (0.58) | ALDH1A1HRH4HRH1SMN1; SMN2USP2 | |
| Hydrochloric Acid SCHEMBL31046022 | 0.92 | HRH1 (0.54) | ALDH1A1HRH4HRH1SMN1; SMN2USP2 | |
| SCHEMBL10453209 | 0.89 | HRH4 (0.59) | HRH4 | |
| SCHEMBL128037 | 0.89 | HRH4 (0.59) | HRH4 | |
| SCHEMBL17144388 | 0.84 | ALDH1A1 (0.47) | ALDH1A1HRH4HRH1SMN1; SMN2USP2 | |
| SCHEMBL11150401 | 0.83 | HRH4 (0.59) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941123-B2 | Triazine precondensate and method for obtaining the same | BOREALIS AGROLINZ MELAMINE GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| EP-3478668-B1 | NOVEL TRIAZINE PRECONDENSATE AND METHOD FOR OBTAINING THE SAME | BOREALIS AGROLINZ MELAMINE (AT) | 2021-02-24 | — | — | EP | disclosed |
| US-20190270714-A1 | Triazine Precondensate and Method for Obtaining the Same | BOREALIS AG (AT) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941123-B2 | Triazine precondensate and method for obtaining the same | NDUFS5, CBR3, MT-ND5 | ALDH1A1 2185/4885HRH4 37/4885HRH1 204/4885 |
| US-20190270714-A1 | Triazine Precondensate and Method for Obtaining the Same | NDUFS5, CBR3, MT-ND5 | ALDH1A1 2185/4885HRH4 37/4885HRH1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.